Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma

Area of Science:

• Uro-oncology
• Biomarker Discovery
• Diagnostic Assays

Background:

• Transitional cell carcinoma (TCC) accounts for 90% of bladder tumors.
• Accurate diagnosis and grading of TCC are crucial for effective treatment.
• Hyaluronan (HA) is a component of the extracellular matrix with potential as a tumor marker.

Purpose of the Study:

• To establish and validate an ultrasensitive assay for measuring urinary hyaluronan (HA).
• To determine the utility of urinary HA levels in the diagnosis and grading of transitional cell carcinoma (TCC).

Main Methods:

• Collected urine samples from 350 patients pre-surgery.
• Measured urinary HA using a noncompetitive enzyme-linked immunosorbent assay (ELISA)-like fluorometric assay.
• Analyzed data using receiver operator characteristic (ROC) curves and statistical tests to evaluate diagnostic performance.

Main Results:

• A urinary HA cutoff of 13.0 μg/l demonstrated 82.3% sensitivity and 81.2% specificity for TCC detection.
• Increased urinary HA levels correlated with higher TCC risk (3.9% increase per 1 μg/l HA).
• Higher HA levels were significantly associated with invasive and high-grade tumors (P < 0.005).

Conclusions:

• Urinary HA shows promise as a non-invasive tumor marker for TCC diagnosis and grading.
• Elevated urinary HA levels correlate with tumor invasiveness and aggressiveness.
• The HA assay provides valuable information for assessing TCC severity and patient prognosis.